---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-006043"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T07:07:50.600049+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Azitra enters up to $20M equity line with Alumni Capital for clinical pipeline funding

## Summary
- Purchase Agreement with Alumni Capital LP for up to $20M of common stock and warrants over 20 months.
- Azitra controls timing/amount of sales; purchase price at 90% of lowest VWAP during pricing period.
- Each purchase includes warrants for 10% of shares at 130% of purchase price, exercisable for 5 years subject to shareholder approval.
- Company must register resale of shares within 60 days; issuance exempt under Section 4(a)(2).
- Proceeds to advance pipeline for Netherton Syndrome and EGFRi-associated rash.

## SEC filing metadata
- accession: 0001641172-25-006043
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000164117225006043/0001641172-25-006043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000164117225006043/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-006043
- JSON: https://secwatch.observer/filing/0001641172-25-006043.json
- Plain text: https://secwatch.observer/filing/0001641172-25-006043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.